Research and Markets (http://www.researchandmarkets.com/research/f0ba11/puerto_rico_pharma)
has announced the addition of the "Puerto
Rico Pharmaceuticals and Healthcare Report Q1 2010" report to their
offering.
“Puerto
Rico Pharmaceuticals and Healthcare Report Q1 2010”
Puerto Rico Pharmaceuticals and Healthcare Report provides industry
professionals and strategists, corporate analysts, pharmaceutical
associations, government departments and regulatory bodies with
independent forecasts and competitive intelligence on Puerto Rico's
pharmaceuticals and healthcare industry.
We expect healthcare spending to rise from US$10.66bn in 2009 to
US$14.49bn by 2014, representing a compound annual growth of 6.3%.
However, GDP contributions toward healthcare will remain at around 16%
during this time, while public sector healthcare spending will fall from
41% to 39%. We have introduced our new 10-year forecast for Puerto Rico
with extensions given to the total drug market, prescription drug
spending, patented, generic and over-the-counter OTC expenditure. The
therapeutic breakdowns will only extend as far as five years. By the end
of 2009, we expect the prescription drug market to comprise 90% of the
total pharmaceutical market. Generic drugs will constitute 22% of the
total market and 25% of the total value of prescription medicine sales,
while patented drugs will comprise 68% of the total drug spending and
75% of the prescription market by the end of 2009.
The pending US healthcare reform has raised concerns for its
unincorporated territory. The current level of underfunding in Puerto
Rican healthcare coverage through its Medicaid and Medicare insurance is
estimated to be approximately US$2.8bn. If the country were viewed as a
US state, it would be able to dramatically increase its budget for
health coverage.